

Recombinant Human Prolactin R Fc Chimera

Catalog Number: 1167-PR

Source	Mouse myeloma cell line, NS0-derived		
	Human Prolactin R (Gln25-Asp234) Accession # P16471	IEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus C-terminus		
N-terminal Sequence Analysis	No results obtained: Gln25 predicted		
Structure / Form	Disulfide-linked homodimer		
Predicted Molecular Mass	51 kDa (monomer)		
SPECIFICATIONS			
SDS-PAGE	66 kDa, reducing conditions		
Activity	Measured by its ability to inhibit Prolactin-induce The ED ₅₀ of this effect is typically 0.04-0.24 μξ	,	,
Activity Endotoxin Level	, ,	g/mL in the presence of 0.5 ng/mL of recombina	,
	The ED $_{50}$ of this effect is typically 0.04-0.24 μ g	g/mL in the presence of 0.5 ng/mL of recombinations.	,
Endotoxin Level	The ED $_{50}$ of this effect is typically 0.04-0.24 μ C <0.10 EU per 1 μ G of the protein by the LAL me	g/mL in the presence of 0.5 ng/mL of recombination. s and visualized by silver stain.	,
Endotoxin Level Purity	The ED $_{50}$ of this effect is typically 0.04-0.24 μ C <0.10 EU per 1 μ G of the protein by the LAL me >90%, by SDS-PAGE under reducing conditions Lyophilized from a 0.2 μ m filtered solution in PE	g/mL in the presence of 0.5 ng/mL of recombination. s and visualized by silver stain.	,
Endotoxin Level Purity Formulation	The ED $_{50}$ of this effect is typically 0.04-0.24 μ C <0.10 EU per 1 μ G of the protein by the LAL me >90%, by SDS-PAGE under reducing conditions Lyophilized from a 0.2 μ m filtered solution in PE	g/mL in the presence of 0.5 ng/mL of recombination. s and visualized by silver stain.	,
Endotoxin Level Purity Formulation PREPARATION AND ST	The ED ₅₀ of this effect is typically 0.04-0.24 µg <0.10 EU per 1 µg of the protein by the LAL me >90%, by SDS-PAGE under reducing conditions Lyophilized from a 0.2 µm filtered solution in PE	g/mL in the presence of 0.5 ng/mL of recombination. Ithod. Is and visualized by silver stain. It is and visualized by silver stain. It is and visualized by silver stain.	ant human Prolactin.
Endotoxin Level Purity Formulation PREPARATION AND ST Reconstitution	The ED ₅₀ of this effect is typically 0.04-0.24 μς <0.10 EU per 1 μg of the protein by the LAL me >90%, by SDS-PAGE under reducing conditions Lyophilized from a 0.2 μm filtered solution in PETORAGE Reconstitute at 100 μg/mL in sterile PBS.	g/mL in the presence of 0.5 ng/mL of recombination. Ithod. Is and visualized by silver stain. Ithos. Itho	ant human Prolactin.
Endotoxin Level Purity Formulation PREPARATION AND ST Reconstitution Shipping	The ED ₅₀ of this effect is typically 0.04-0.24 μς <0.10 EU per 1 μg of the protein by the LAL me >90%, by SDS-PAGE under reducing conditions Lyophilized from a 0.2 μm filtered solution in PE FORAGE Reconstitute at 100 μg/mL in sterile PBS. The product is shipped at ambient temperature.	g/mL in the presence of 0.5 ng/mL of recombination. Is and visualized by silver stain. It is an an all visualized by silver stain. It is an all visualized by silver stain.	ant human Prolactin.

BACKGROUND

The neuroendocrine pituitary hormone Prolactin (PRL), also known as lactotrophin, mamotrophin, luteotropic hormone (LTH), or luteotropin, is a secreted hormone that affects reproduction and homeostasis in vertebrates. The functions of PRL can be placed in six broad categories: 1) reproduction and lactation; 2) growth and development; 3) endocrinology and metabolism; 4) brain and behavior; 5) immunomodulation; and 6) electrolyte balance (1, 2). PRL is secreted by the anterior pituitary gland, mammary gland, placenta, brain, uterus, decidua, dermal fibroblasts, B cells, T cells, NK cells, and some breast cancer cell lines. Although the major form of PRL is a 23 kDa monomeric protein, splice variants of 14, 16, and 22 kDa have been identified. PRL has also been found to be glycosylated, phosphorylated, dimerized, and polymerized. Glycosylation, phosphorylation, dimerization, or polymerization of PRL result in lower activity (2).

Cell activation by PRL is mediated by a single chain membrane-bound protein belonging to the class 1 cytokine superfamily. The PRL receptor (PRL R) contains an extracellular, transmembrane, and intracellular domain. Transcriptional regulation of the PRL R gene results in several different species-dependent isoforms of PRL R being produced. Although the cytoplasmic domains of the different isoforms vary in length and composition, their extracellular domains are identical. In rats, three major PRL receptor isoforms have been described, a short (291 amino acid), an intermediate (393 amino acid), and a long (591 amino acid) (2). PRL receptors are found in mammary tissue, pituitary gland, brain, heart, lung thymus, spleen, liver, pancreas, kidney, adrenal gland, uterus, skeletal muscle, and skin (3). A soluble form of PRL-R containing the 206 NH₂-terminal amino acids of the extracellular domain is secreted by mammary epithelial cells and is found in milk. Binding of the transmembrane PRL R results in ligand dimerization followed by binding and phosphorylation of Jak2. Jak2 then phosphorylates STAT and the long form of PRL R. C-src, fyn, and the Ras/Raf/MAP kinase pathway have also been found to be activated upon PRL R ligand binding (2).

References:

- 1. Kelly, P.A. et al. (2001) Biochem. Society Transaction 29:48.
- 2. Freeman, M.E. et al. (2000) Physiol. Rev. 80:1532.
- 3. Nagano, M. and P.A. Kelly (1994) J. Biol. Chem. 269:13337.

